Leishmania major infection in humanized mice induces systemic infection and provokes a nonprotective human immune response

PLoS Neglected Tropical Diseases

Volumn 6, Issue 7, 2012, Pages

  Wege, Anja Kathrin ^a   Florian, Christian ^a   Ernst, Wolfgang ^a   Zimara, Nicole ^a   Schleicher, Ulrike ^b   Hanses, Frank ^c   Schmid, Maximilian ^a   Ritter, Uwe ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^c UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CD27 ANTIGEN; CD4 ANTIGEN; CD45RA ANTIGEN; CD8 ANTIGEN; INDUCIBLE NITRIC OXIDE SYNTHASE; MILTEFOSINE; ANTIPROTOZOAL AGENT; DRUG DERIVATIVE; PHOSPHORYLCHOLINE;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; FLOW CYTOMETRY; HISTOLOGY; HOST PARASITE INTERACTION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE MICROSCOPY; INNATE IMMUNITY; LEISHMANIA MAJOR; LEISHMANIASIS; MACROPHAGE; MONONUCLEAR CELL; MOUSE; NEWBORN; NONHUMAN; PARASITE LOAD; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE ACTIVATION; ANIMAL; DISEASE MODEL; IMMUNE EVASION; IMMUNOLOGY; MOUSE MUTANT; PATHOGENICITY; PATHOLOGY; SKIN LEISHMANIASIS; TREATMENT OUTCOME;

ANIMALS; ANTIPROTOZOAL AGENTS; DISEASE MODELS, ANIMAL; HUMANS; IMMUNE EVASION; LEISHMANIA MAJOR; LEISHMANIASIS, CUTANEOUS; MICE; MICE, SCID; PHOSPHORYLCHOLINE; TREATMENT OUTCOME;

EID: 84864601779     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0001741     Document Type: Article

References (72)

1. Scott P, (2003) Development and regulation of cell-mediated immunity in experimental leishmaniasis. Immunol Res 27: 489-98.
2. Bogdan C, (2001) Nitric oxide and the immune response. Nat Immunol 2(10): 907-16.
3. Sacks D, Noben-Trauth N, (2002) The immunology of susceptibility and resistance to Leishmania major in mice. Nat Rev Immunol 2: 845-858.
4. Solbach W, Laskay T, (2000) The host response to Leishmania infection. Adv Immunol 74: 275-317.
5. Alexander J, Bryson K, (2005) T helper T(h)1/Th2 and Leishmania: paradox rather than paradigm. Immunol Lett 99: 17-23.
6. Doeing DC, Borowicz JL, Crockett ET, (2000) Gender dimorphism in differential peripheral blood leukocyte counts in mice using cardiac, tail, foot, and saphenous vein puncture methods. BMC Clin Pathol 3: 3.
7. Gantt KR, Goldman TL, McCormick ML, Miller MA, Jeronimo SM, et al. (2001) Oxidative responses of human and murine macrophages during phagocytosis of Leishmania chagasi. J Immunol 167: 893-901.
8. Ritter U, Moll H, (2000) Monocyte chemotactic protein-1 stimulates the killing of leishmania major by human monocytes, acts synergistically with IFN-gamma and is antagonized by IL-4. Eur J Immunol 30: 3111-20.
9. Brandonisio O, Panaro MA, Sisto M, Acquafredda A, Fumarola L, et al. (2001) Nitric oxide production by Leishmania-infected macrophages and modulation by cytokines and prostaglandins. Parassitologia 43 (Suppl 1): 1-6.
10. Murray HW, Nathan CF, (1999) Macrophage microbicidal mechanisms in vivo: reactive nitrogen versus oxygen intermediates in the killing of intracellular visceral Leishmania donovani. J Exp Med 189: 741-6.
11. Qadoumi M, Becker I, Donhauser N, Röllinghoff M, Bogdan C, (2002) Expression of inducible nitric oxide synthase in skin lesions of patients with American cutaneous leishmaniasis. Infect Immun 70: 4638-42.
12. Zhang X, Laubach VE, Alley EW, Edwards KA, Sherman PA, et al. (1996) Transcriptional basis for hyporesponsiveness of the human inducible nitric oxide synthase gene to lipopolysaccharide/interferon-gamma. J Leukoc Biol 59: 575-85.
13. Schneemann M, Schoedon G, (2002) Species differences in macrophage NO production are important. Nat Immunol 3: 102.
14. McGwire BS, Olson CL, Tack BF, Engman DM, (2003) Killing of African trypanosomes by antimicrobial peptides. J Infect Dis 188: 146-52.
15. Risso A, (2000) Leukocyte antimicrobial peptides: multifunctional effector molecules of innate immunity. J Leukocyte Biol 68: 785.
16. Ouellette AJ, Selsted ME, (1996) Paneth cell defensins: endogenous peptide components of intestinal host defense. FASEB J10: 1280.
17. Barnaba V, Watts C, de Boer M, Lane P, Lanzavecchia A, (1994) Professional presentation of antigen by activated human T cells. Eur J Immunol 24: 71-5.
18. Mestas J, Hughes CC, (2004) Of mice and not men: differences between mouse and human immunology. J Immunol 172: 2731-8.
19. Ishikawa F, Yasukawa M, Lyons B, Yoshida S, Miyamoto T, et al. (2005) Development of functional human blood and immune systems in NOD/SCID/IL2 receptor {gamma} chain(null) mice. Blood 106: 1565-73.
20. Ito M, Hiramatsu H, Kobayashi K, Suzue K, Kawahata M, et al. (2002) NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood 100: 3175-82.
21. Shultz LD, Lyons BL, Burzenski LM, Gott B, Chen X, et al. (2005) Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol 174: 6477-89.
22. Shultz LD, Ishikawa F, Greiner DL, (2007) Humanized mice in translational biomedical research. Nat Rev Immunol 7: 118-30.
23. Aldrovandi GM, Feuer G, Gao L, Jamieson B, Kristeva M, et al. (1993) The SCID-hu mouse as a model for HIV-1 infection. Nature 363: 732-6.
24. Denton PW, Estes JD, Sun Z, Othieno FA, Wei BL, et al. (2008) Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice. PLoS Med 5: e16.
25. Melkus MW, Estes JD, Padgett-Thomas A, Gatlin J, Denton PW, et al. (2006) Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1. Nat Med 12: 1316-22.
26. Sun Z, Denton PW, Estes JD, Othieno FA, Wei BL, et al. (2007) Intrarectal transmission, systemic infection, and CD4+ T cell depletion in humanized mice infected with HIV-1. J Exp Med 204: 705-14.
27. Wege AK, Melkus MW, Denton PW, Estes JD, Garcia JV, (2008) Functional and phenotypic characterization of the humanized BLT mouse model. Curr Top Microbiol Immunol 324: 149-65.
28. Vlad G, Stokes MB, Liu Z, Chang CC, Sondermeijer H, et al. (2009) Suppression of xenogeneic graft-versus-host disease by treatment with immunoglobulin-like transcript 3-Fc. Hum Immunol 70: 663-9.
29. Subramanya S, Kim SS, Abraham S, Yao J, Kumar M, et al. (2009) Targeted delivery of siRNA to human dendritic cells to suppress Dengue viral infection and associated proinflammatory cytokine production. J Virol 84: 2490-501.
30. Strowig T, Gurer C, Ploss A, Liu YF, Arrey F, et al. (2009) Priming of protective T cell responses against virus-induced tumors in mice with human immune system components. J Exp Med 206: 1423-34.
31. Joseph A, Zheng JH, Chen K, Dutta M, Chen C, et al. (2010) Inhibition of In Vivo HIV Infection In Humanized Mice By Gene Therapy of Human Hematopoietic Stem Cells with a Lentiviral Vector Encoding a Broadly Neutralizing Anti-HIV Antibody. J Virol 84: 6645-53.
32. Canale S, Cocco C, Frasson C, Seganfreddo E, Di Carlo E, et al. (2011) Interleukin-27 inhibits pediatric B-acute lymphoblastic leukemia cell spreading in a preclinical model. Leukemia 25: 1815-24.
33. Cai S, Wang H, Bailey B, Ernstberger A, Juliar BE, et al. (2011) Humanized Bone Marrow Mouse Model as a Preclinical Tool to Assess Therapy-Mediated Hematotoxicity. Clin Cancer Res 17: 2195-2206.
34. Herwaldt BL, (1999) Miltefosine-the long-awaited therapy for visceral leishmaniasis? N Engl J Med 341: 1840-2.
35. Kuhlencord A, Maniera T, Eibl H, Unger C, (1992) Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice. Antimicrob Agents Chemother 36: 1630-4.
36. Kedzierski L, Sakthianandeswaren A, Curtis JM, Andrews PC, Junk PC, et al. (2009) Leishmaniasis: current treatment and prospects for new drugs and vaccines. Curr Med Chem 16: 599-614.
37. Wege AK, Ernst W, Eckl J, Frankenberger B, Vollmann-Zwerenz A, et al. (2011) Humanized tumor mice-A new model to study and manipulate the immune response in advanced cancer therapy. Int J Cancer doi:10.1002/ijc.26159 (Epub ahead of print).
38. Ritter U, Meissner A, Scheidig C, Körner H, (2004) CD8 alpha- and Langerin-negative dendritic cells, but not Langerhans cells, act as principal antigen-presenting cells in leishmaniasis. Eur J Immunol 34: 1542-50.
39. Karamian M, Motazedian MH, Mehrabani D, Gholami K, (2007) Leishmania major infection in a patient with visceral leishmaniasis: treatment with Amphotericin B. Parasitol Res 101: 1431-4.
40. Turetz ML, Machado PR, Ko AI, Alves F, Bittencourt A, et al. (2002) Disseminated leishmaniasis: a new and emerging form of leishmaniasis observed in northeastern Brazil. J Infect Dis 186: 1829-34.
41. Hepburn NC, (2000) Cutaneous leishmaniasis. Clin Exp Dermatol 25: 363-70.
42. Wilhelm P, Ritter U, Labbow S, Donhauser N, Röllinghoff M, et al. (2001) Rapidly fatal leishmaniasis in resistant C57BL/6 mice lacking TNF. J Immunol 166: 4012-9.
43. Cher DJ, Mosmann TR, (1987) Two types of murine helper T cell clone. II. Delayed-type hypersensitivity is mediated by TH1 clones. J Immunol 138: 3688-94.
44. Mings S, Beck JC, Davidson C, Ondo AL, Shanler SD, et al. (2009) Cutaneous leishmaniasis with boggy induration and simultaneous mucosal disease. Am J Trop Med Hyg 80: 3-5.
45. Strowig T, Gurer C, Ploss A, Liu YF, Arrey F, et al. (2009) Priming of protective T cell responses against virus-induced tumors in mice with human immune system components. J Exp Med 206: 1423-34.
46. Mota J; Rico-Hesse R, (2009) Humanized mice show clinical signs of dengue fever according to infecting virus genotype. J Virol 83: 8638-45.
47. Gorantla S, Makarov E, Finke-Dwyer J, Gebhart CL, Domm W, et al. (2010) CD8+ Cell Depletion Accelerates HIV-1 Immunopathology in Humanized Mice. J Immunol 184: 7082-91.
48. Bohana-Kashtan O, Morisot S, Hildreth R, Brayton C, Levitsky HI, et al. (2009) Selective reduction of graft-versus-host disease-mediating human T cells by ex vivo treatment with soluble Fas ligand. J Immunol 183: 696-705.
49. Magill AJ, Grögl M, Gasser RA Jr, Sun W, Oster CN, (1993) Visceral infection caused by Leishmania tropica in veterans of Operation Desert Storm. N Engl J Med 328: 1383-7.
50. Karamian M, Motazedian MH, Mehrabani D, Gholami K, (2007) Leishmania major infection in a patient with visceral leishmaniasis: treatment with Amphotericin B. Parasitol Res 101: 1431-4.
51. Barro-Traoré F, Preney L, Traoré A, Darie H, Tapsoba P, et al. (2008) Cutaneous leishmaniasis due to Leishmania major involving the bone marrow in an AIDS patient in Burkina Faso. Ann Dermatol Venereol 135: 380-3.
52. Magill AJ, Grögl M, Gasser RA Jr, Sun W, Oster CN, (1993) Visceral infection caused by Leishmania tropica in veterans of Operation Desert Storm. N Engl J Med 328: 1383-7.
53. Solbach W, Forberg K, Kammerer E, Bogdan C, Röllinghoff M, (1986) Suppressive effect of cyclosporin A on the development of Leishmania tropica-induced lesions in genetically susceptible BALB/c mice. J Immunol 137: 702-7.
54. Ritter U, Mattner J, Rocha JS, Bogdan C, Körner H, (2004) The control of Leishmania (Leishmania) major by TNF in vivo is dependent on the parasite strain. Microbes Infect 6: 559-65.
55. Mock BA, Fortier AH, Potter M, Nacy CA, (1985) Genetic control of systemic Leishmania major infections: dissociation of intrahepatic amastigote replication from control by the Lsh gene. Infect Immun 50: 588-91.
56. Laskay T, Wittmann I, Diefenbach A, Röllinghoff M, Solbach W, (1997) Control of Leishmania major infection in BALB/c mice by inhibition of early lymphocyte entry into peripheral lymph nodes. J Immunol 158: 1246-53.
57. Ritter U, Mattner J, Rocha JS, Bogdan C, Körner H, (2004) The control of Leishmania (Leishmania) major by TNF in vivo is dependent on the parasite strain. Microbes Infect 6: 559-65.
58. Diefenbach A, Schindler H, Donhauser N, Lorenz E, Laskay T, et al. (1998) Type 1 interferon (IFNalpha/beta) and type 2 nitric oxide synthase regulate the innate immune response to a protozoan parasite. Immunity 8: 77-87.
59. Mock BA, Fortier AH, Potter M, Nacy CA, (1985) Genetic control of systemic Leishmania major infections: dissociation of intrahepatic amastigote replication from control by the Lsh gene. Infect Immun 50: 588-91.
60. Laskay T, Diefenbach A, Röllinghoff M, Solbach W, (1995) Early parasite containment is decisive for resistance to Leishmania major infection. Eur J Immunol 25: 2220-7.
61. Shultz L D, Schweitzer PA, Christianson SW, Gott B, Schweitzer IB, et al. (1995) Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. J Immunol 154: 180-191.
62. Traggiai E, Chicha L, Mazzucchelli L, Bronz L, Piffaretti JC, et al. (2004) Development of a human adaptive immune system in cord blood cell-transplanted mice. Science 304: 104-7.
63. Lee YJ, Jeon YK, Kang BH, Chung DH, Park CG, et al. (2010) Generation of PLZF+ CD4+ T cells via MHC class II-dependent thymocyte-thymocyte interaction is a physiological process in humans. J Exp Med 207: 237-46.
64. Thang MN, Thang DC, Chelbi-Alix MK, Robert-Galliot B, Commoy-Chevalier MJ, et al. (1979) Human leukocyte interferon: relationship between molecular structure and species specificity. Proc Natl Acad Sci U S A 76: 3717-21.
65. Blos M, Schleicher U, Soares Rocha FJ, Meissner U, Röllinghoff M, et al. (2003) Organ-specific and stage-dependent control of Leishmania major infection by inducible nitric oxide synthase and phagocyte NADPH oxidase. Eur J Immunol 33: 1224-34.
66. Arevalo I, Ward B, Matlashewski G, (2002) Detection of iNOS gene expression in cutaneous leishmaniasis biopsy tissue. Mol Biochem Parasitol 121: 145-7.
67. Bogdan C, Röllinghoff M, (1998) The immune response to Leishmania: mechanisms of parasite control and evasion. Int J Parasitol 28: 121-34.
68. Filipe-Santos O, Pescher P, Breart B, Lippuner C, Aebischer T, et al. (2009) A dynamic map of antigen recognition by CD4 T cells at the site of Leishmania major infection. Cell Host Microbe 6: 23-33.
69. Sundar S, Olliaro PL, (2007) Miltefosine in the treatment of leishmaniasis: Clinical evidence for informed clinical risk management. Ther Clin Risk Manag 3: 733-40.
70. Jha TK, Sundar S, Thakur CP, Bachmann P, Karbwang J, et al. (1999) Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. N Engl J Med 341: 1795-800.
71. Hochhuth CH, Vehmeyer K, Eibl H, Unger C, (1992) Hexadecylphosphocholine induces interferon-gamma secretion and expression of GM-CSF mRNA in human mononuclear cells. Cell Immunol 141: 161-8.
72. Zeisig R, Rudolf M, Eue I, Arndt D, (1995) Influence of hexadecylphosphocholine on the release of tumor necrosis factor and nitroxide from peritoneal macrophages in vitro. J Cancer Res Clin Oncol 121: 69-75.